NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球醫藥品受託製造開發機關(CDMO)市場(2020年∼2027年)

Global Pharmaceutical Contract Development and Manufacturing Market - 2020-2027

出版商 DataM Intelligence 商品編碼 1004497
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
全球醫藥品受託製造開發機關(CDMO)市場(2020年∼2027年) Global Pharmaceutical Contract Development and Manufacturing Market - 2020-2027
出版日期: 2021年05月10日內容資訊: 英文 180 Pages
簡介

由於藥物研發的投資和支出增加以及醫療機構降低醫療成本的壓力增加,合同製造組織(CDMO)市場預計將增長。此外,為提高治療效果和安全性對仿製藥和生物製藥的需求不斷增長,預計將進一步擴大全球藥品的合同開發和製造。此外,由於對細胞治療和基因治療的需求不斷增加,預計市場將在預測期內擴大。然而,與藥物批准相關的監管複雜性是阻礙市場增長的一個因素。

本報告提供全球醫藥品受託製造開發機關(CDMO)市場調查市場調查,彙整市場概要,市場區隔·各地區的市場規模及成長率的變化與預測,新型冠狀病毒感染疾病(COVID-19)的影響分析,市場成長的推動要素及阻礙因素分析,市場機會,價格及貿易趨勢,競爭情形,主要企業簡介等資訊。

目錄

第1章 調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 市場定義和概要

第3章 摘要整理

  • 市場明細:各類服務
  • 市場明細:各終端用戶
  • 市場明細:各地區

第4章 市場動態

  • 市場影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求
  • 專利趨勢

第6章 新型冠狀病毒感染疾病(COVID-19)的影響分析

  • 新型冠狀病毒感染疾病(COVID-19)的影響分析
    • COVID-19前的市場方案
    • 目前市場方案
    • COVID-19後的市場方案
  • COVID-19疫情下價格趨勢
  • 供需頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 總論

第7章 全球醫藥品受託製造開發機關(CDMO)市場:各類服務

  • 簡介
  • 市場規模·與前一年同期比較成長率分析:各類服務
  • 市場魅力指數:各類服務
    • 醫藥品製造服務
    • 藥物研發服務
    • 生技藥品製造服務

第8章 全球醫藥品受託製造開發機關(CDMO)市場:各終端用戶

  • 簡介
  • 市場規模·與前一年同期比較成長率分析:各終端用戶
  • 市場魅力指數:各終端用戶
    • 大型製藥企業
    • 中小製藥企業
    • 非專利處方藥企業
    • 其他

第9章 全球醫藥品受託製造開發機關(CDMO)市場:各地區

  • 簡介
  • 市場規模分析·與前一年同期比較成長率:各地區
  • 市場魅力指數:各地區
  • 北美
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類服務
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 歐洲
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類服務
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 南美
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類服務
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 亞太地區
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類服務
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 中東·非洲
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類服務
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國

第10章 競爭情形

  • 競爭模式
  • 市場定位/股票分析
  • 合併·收購分析

第11章 企業簡介

  • Lonza Group
    • 企業概要
    • 產品系列
    • 主要的焦點
    • 財務形勢
  • Thermo Fisher Scientific Inc.
  • Catalent
  • Recipharm AB
  • ABBVIE
  • Siegfried Holding AG
  • Evonik Industries
  • Boehringer Ingelheim
  • Piramal Pharma Limited
  • Fujifilm Healthcare
  • Asymchem Laboratories(Tianjin)Co., Ltd.
  • WuXi AppTec
  • 其他的企業

第12章 重要考察

第13章 關於DataM Intelligence

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

Contract development and manufacturing organization (CDMO), also known as contract manufacturing organization (CMO), is a company that provide services to other companies in the pharmaceutical industry on a contract basis range from drug development to drug manufacturing. On the other hand, the CDMO is a combination of development and manufacturing of pharmaceutical products by different companies on a contractual basis that are constrained by a certain set of standards and rules that each company must need to adhere. In this context, all the pharmaceutical companies act as outsourcing companies that deal with the manufacturing and development of drugs that lead to improved business scalability and revenue. Also, many companies are significantly investing in these services, as it inherently provides cost-saving and time-saving benefits resulting in a maximum stake of outsourcing revenue. As such, the need for pharmaceutical contract development and manufacturing treatment is gaining significant momentum in recent years to deliver value-added services for a risk-sharing or integrated business model.

The global pharmaceutical contract development and manufacturing market size was worth US$ XX billion in 2020 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

The growth in investments and spending on pharmaceutical research and development (R&D) coupled with the increasing pressure on healthcare providers to reduce healthcare cost is expected to propel the market growth. Furthermore, the rising demand for generics medicine and biologics to improve the therapeutic effectiveness and safety profiles for the health conditions will further enhance the demand for pharmaceutical contract development and manufacturing market globally. However, the limited outsourcing activities among well-established pharma companies' customers, along with regulatory complication associated with the drug approval are the few factors that may hamper the market growth during the forecast period. Moreover, the growing demand for cell and gene therapies is expected to fuel the penetration of the pharmaceutical contract development and manufacturing market during the forecast period.

Mounting Pressure on Pharmaceutical Providers to Reduce Healthcare Costs

As the current market trend, the healthcare sector requires to deliver improved patient care and enhance the patient's experience from the initial stage of the diagnosis till the recovery phase within or outside the healthcare organizations. Through which pharmaceutical companies are opting for pharmaceutical outsourcing services that can free an organization to concentrate on non-critical tasks and helps them to focus resources on core competencies, which further leads to the significant reduction of overall healthcare cost. As per the Insight customer call solution LTD, the appointment of BPO in the pharmaceutical and healthcare industries may lead to saving the additional cost of up to 30-60%. As such, the utility of pharmaceutical outsourcing and manufacturing activities have a prominent role in the reduction of healthcare cost.

Moreover, many automated solutions complied with complete software & skilled professionals that helps in managing efficient development of drugs and medicines, which further reduce the cost of hiring additional staff, training them and investment cost of others related resource. As a result, the inclined pressure on healthcare providers to lower healthcare cost is expected to drive the growth of the market over the forecast years.

Rapid growth in pharmaceutical products consumption in the Asia Pacific

As per the recent demographic condition, the growth in consumption of pharmaceutical products rely on the development of pharmaceutical contract development and manufacturing industry and it is rapidly increasing across the Asia Pacific region, owing to an increase in the purchasing power and growing development and consumption of novel drugs and medicines among the target audiences. The demand is also enhanced due to its improved usage in pharmaceutical outsourcing activities to meet the unmet medical needs and further replace traditional techniques and systems.

In addition, widening pharmaceutical contract development and manufacturing market opportunities is primarily driven by the surging demand for generic and speciality drugs in the Asian countries are further reinforced the product demand in the region. Pharmaceutical sector growth in the Asian economy is feasible due to growing healthcare infrastructure, increased pharmaceutical and biopharmaceutical companies, and rising target populations. Supplementary driving factors to industry growth include changing companies preferences to outsource the other critical areas to focus on the development of drugs is further promoting the consumption of pharmaceutical products, which, in turn, driving the market growth during the forecast period.

COVID-19 Impact Analysis

COVID-19 pandemic has affected the global economy in several terms, such as directly impacting the production and demand, supply chain disruption, and financial impact. With the COVID-19 disruptions in various sectors, the manufacturers' supply chain in the healthcare sector has significantly improved on a global scale to control the spread of novel coronavirus diseases. However, the ongoing pandemic further resulted in shutting down the production facilities to minimize the risk of virus spread. This has led to the implementation of lockdown policies that have a significant impact on pharmaceutical outsourcing actives throughout the world to meet high unmet medical needs among patients. Therefore, the manufacturers are keen to invest and expand their production capabilities to meet the global market's updated demand.

Despite the pandemic, there is a huge growth has been witnessed in the overall pharmaceutical products, which is expected to drive the pharmaceutical contract development and manufacturing's market size in the global market during the forecast period.

Segment Analysis

Based on the services, the pharmaceutical contract development and manufacturing market has been classified into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services.

Biologics manufacturing services segment accounted for the highest market share in the global market

In 2019, the biologics manufacturing services segment was anticipated to account for the largest share, owing to the rise in availability of biological services by numerous market players, along with growing demand for vaccine and biosimilars. Such products reduce the overall investment needed to bring a new product to market, offering access to expensive technologies, and improved flexibility are some benefits offered by CMOs, which have prompted the companies to use their biologics manufacturing services.

Moreover, the biologics manufacturing service is also expected to register significant growth in the overall market. This is due to the robust pipeline of new biological drugs due to the growing commercial success of biopharma companies across developed and developing economies is paving the growth of the biologics manufacturing services segment in the global pharmaceutical contract development and manufacturing market during the forecast period.

Based on the end-user, the pharmaceutical contract development and manufacturing market has been classified into large pharmaceutical companies, small and mid-sized pharmaceutical companies, generic pharmaceutical companies, and others.

Large pharmaceutical companies segment dominated the global pharmaceutical contract development and manufacturing market in 2019

In 2019, the large pharmaceutical companies segment dominated the pharmaceutical contract development and manufacturing market, owing to the high demand for end-to-end services from these companies, and this is the viable and efficient choice for the pharmaceutical contract development and manufacturing diagnosis. It is also expected that the large companies are also expected to grow with a significant CAGR during the forecast period, owing to they involved in precise drug development processes for pharmaceutical contract development and manufacturing industry in the forecasting period.

Geographical Analysis

Based on geography, the study analyzes the pharmaceutical contract development and manufacturing market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America dominates the global pharmaceutical contract development and manufacturing market in terms of value and volume due to the rise in the number of leading pharmaceutical manufacturing companies and easy accessibility of high-quality pharmaceutical products for healthcare facilities across the region. It is also leading as a consequence of significant expansion that has been made in the U.S. healthcare industry, which, in turn, accelerating the market growth in the region. While in Europe, the rising number of clinical trials and robust growth in the generics industry are the few factors expanding the scope of the global pharmaceutical contract development and manufacturing market in the coming years.

The Asia Pacific is estimated to grow at the pharmaceutical contract development and manufacturing market's highest growth rate during the forecast period. The growth of the region is attributing to the increasing number of mergers & acquisition between Asia-based companies and other international key players, along with improving pharmaceutical facilities in the region. Also, the global companies are investing a substantial amount of funds to increase the export from the low-cost area, which is further likely to increase the pharmaceutical contract development and manufacturing diagnostic products in the domestic region during the forecast period.

Competitive Landscape

The pharmaceutical contract development and manufacturing market is highly competitive, owing to the presence of big pharmaceutical brands. The key Pharmaceutical contract development and manufacturing players which are contributing to the growth of the global market include Lonza Group, Thermo Fisher Scientific Inc., Catalent, Recipharm AB, ABBVIE, Siegfried Holding AG, Evonik Industries, Boehringer Ingelheim, Piramal Pharma Limited, Fujifilm Healthcare, Asymchem Laboratories (Tianjin) Co., Ltd., WuXi AppTec, among others. The major players are adopting new product launch and expansion strategies for global growth in the Pharmaceutical contract development and manufacturing market.

Thermo Fisher Scientific

Overview: Thermo Fisher Scientific was based in Massachusetts, U.S. since 1956. The company is a significant manufacturer and provider in serving instruments and reagents concerning the life sciences area. Further, the company primarily manage an extensive base of the products in laboratory reagents and consumables, science software and services for research, analytical equipment and instruments, discovery, analysis, and manufacturing (including pharmaceutical and diagnostic products). Further, the company has 238 office locations within 48 countries around North America, Latin America, Europe, Asia-Pacific, and the Middle East countries.

Product Portfolio: The company delivers an end-to-end product offering in contract development and manufacturing that includes API, viral vector services, biologics, early and late phase development, cGMP plasmids, logistics services, clinical trial solutions, and commercial manufacturing. It further provides contract services in the areas of Bioanalytical Services, Biologics Manufacturing, Biologics Process Development, Clinical Trials, Analytical laboratory service, and more.

Why Purchase the Report?

  • Visualize the pharmaceutical contract development and manufacturing market segmentation composition by service, end-user, and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the pharmaceutical contract development and manufacturing market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Pharmaceutical contract development and manufacturing market - level 3 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Pharmaceutical contract development and manufacturing market report would provide access to an approx. 54 market data table, 46 figures and 276 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Pharmaceutical Contract Development and Manufacturing Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Pharmaceutical Contract Development and Manufacturing Market - Market Definition and Overview

3. Global Pharmaceutical Contract Development and Manufacturing Market - Executive Summary

  • 3.1. Market Snippet by Service
  • 3.2. Market Snippet by End-User
  • 3.3. Market Snippet by Region

4. Global Pharmaceutical Contract Development and Manufacturing Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Surging demand as a concern of ongoing patent cliff of the biologic drugs
      • 4.1.1.2. Increasing utility of pharmaceutical outsourcing support
      • 4.1.1.3. Rising demand for generics medicine and biologics
    • 4.1.2. Restraints:
      • 4.1.2.1. Limited outsourcing activities among well-established pharma companies' customers
      • 4.1.2.2. Regulatory complication associated with the drug approval
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Pharmaceutical Contract Development and Manufacturing Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. Global Pharmaceutical Contract Development and Manufacturing Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Pharmaceutical Contract Development and Manufacturing Market - By Service

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Segment
  • 7.3. Market Attractiveness Index, By Service Segment
    • 7.3.1. Pharmaceutical Manufacturing Services
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Drug Development Services
    • 7.3.3. Biologics Manufacturing Services

8. Global Pharmaceutical Contract Development and Manufacturing Market - By End-User

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 8.3. Market Attractiveness Index, By End-User Segment
    • 8.3.1. Large Pharmaceutical Companies
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Small and Mid-Sized Pharmaceutical Companies
    • 8.3.3. Generic Pharmaceutical Companies
    • 8.3.4. Others

9. Global Pharmaceutical Contract Development and Manufacturing Market - By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Global Pharmaceutical Contract Development and Manufacturing Market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Pharmaceutical Contract Development and Manufacturing Market- Company Profiles

  • 11.1. Lonza Group
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Thermo Fisher Scientific Inc.
  • 11.3. Catalent
  • 11.4. Recipharm AB
  • 11.5. ABBVIE
  • 11.6. Siegfried Holding AG
  • 11.7. Evonik Industries
  • 11.8. Boehringer Ingelheim
  • 11.9. Piramal Pharma Limited
  • 11.10. Fujifilm Healthcare
  • 11.11. Asymchem Laboratories (Tianjin) Co., Ltd.
  • 11.12. WuXi AppTec
  • 11.13. Others

LIST NOT EXHAUSTIVE

12. Global Pharmaceutical Contract Development and Manufacturing Market - Premium Insights

13. Global Pharmaceutical Contract Development and Manufacturing Market - DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us